Gain Therapeutics Inc (NASDAQ: GANX) on Friday, soared 11.46% from the previous trading day, before settling in for the closing price of $3.14. Within the past 52 weeks, GANX’s price has moved between $1.41 and $3.40.
Annual sales at Healthcare sector company slipped by -37.02% over the past five years. The company achieved an average annual earnings per share of 27.42%. With a float of $34.78 million, this company’s outstanding shares have now reached $35.98 million.
Gain Therapeutics Inc (GANX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Gain Therapeutics Inc is 3.64%, while institutional ownership is 12.03%.
Gain Therapeutics Inc (GANX) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.08 earnings per share (EPS) for the period topping the consensus outlook (set at -0.19) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.30% during the next five years compared to -37.02% drop over the previous five years of trading.
Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators
Gain Therapeutics Inc (GANX) is currently performing well based on its current performance indicators. A quick ratio of 2.52 was reported for the most recent quarter. For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Gain Therapeutics Inc (GANX)
Gain Therapeutics Inc (NASDAQ: GANX) saw its 5-day average volume 1.09 million, a positive change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 73.61%.
During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 93.36%, which indicates a significant increase from 90.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.34 in the past 14 days, which was higher than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.16, while its 200-day Moving Average is $1.93. Nevertheless, the first resistance level for the watch stands at $3.72 in the near term. At $3.93, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.21. If the price goes on to break the first support level at $3.22, it is likely to go to the next support level at $2.93. The third support level lies at $2.72 if the price breaches the second support level.
Gain Therapeutics Inc (NASDAQ: GANX) Key Stats
Market capitalization of the company is 126.34 million based on 36,241K outstanding shares. Right now, sales total 0 K and income totals -20,410 K. The company made 0 K in profit during its latest quarter, and -5,280 K in sales during its previous quarter.
